These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32552055)

  • 1. Gross profits of Canadian pharmacies: A changing policy regime.
    Thanh NX; Jacobs P; Husereau D
    Healthc Manage Forum; 2020 Sep; 33(5):228-232. PubMed ID: 32552055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Balancing medicine prices and business sustainability: analyses of pharmacy costs, revenues and profit shed light on retail medicine mark-ups in rural Kyrgyzstan.
    Waning B; Maddix J; Soucy L
    BMC Health Serv Res; 2010 Jul; 10():205. PubMed ID: 20626904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in Prescription Drug Prices by Retail Pharmacy Type: A National Cross-sectional Study.
    Luo J; Kulldorff M; Sarpatwari A; Pawar A; Kesselheim AS
    Ann Intern Med; 2019 Nov; 171(9):605-611. PubMed ID: 31569218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of brand-name drug prices between Canadian-based Internet pharmacies and major U.S. drug chain pharmacies.
    Quon BS; Firszt R; Eisenberg MJ
    Ann Intern Med; 2005 Sep; 143(6):397-403. PubMed ID: 16172438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges for Managed Care from 340B Contract Pharmacies.
    Fein AJ
    J Manag Care Spec Pharm; 2016 Mar; 22(3):197-203. PubMed ID: 27003548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers.
    Morgan SG; Thomson PA; Daw JR; Friesen MK
    Health Policy; 2013 Oct; 112(3):248-54. PubMed ID: 23809914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reforming the Swedish pharmaceuticals market: consequences for costs per defined daily dose.
    Bergman MA; Granlund D; Rudholm N
    Int J Health Econ Manag; 2016 Sep; 16(3):201-214. PubMed ID: 27878673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in manufacturer prices of brand name prescription drugs used by older Americans--first quarter 2004 update.
    Gross DJ; Schondelmeyer SW; Raetzman SO
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2004 Jun; (IB69):1-12, 1-2. PubMed ID: 15368653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 340b Program, Contract Pharmacies, Hospitals, and Patients: An Evolving Relationship Impacting Health Care Delivery.
    Ruley M; Belcher M; Sayre H; Coustasse A
    Health Care Manag (Frederick); 2019; 38(4):311-321. PubMed ID: 31663869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacy Benefit Manager Pricing and Spread Pricing for High-Utilization Generic Drugs.
    Mattingly TJ; Ben-Umeh KC; Bai G; Anderson GF
    JAMA Health Forum; 2023 Oct; 4(10):e233660. PubMed ID: 37862035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do generics offer significant savings to the UK National Health Service?
    Kanavos P
    Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of a Beverage Tax on Sugar-Sweetened and Artificially Sweetened Beverages With Changes in Beverage Prices and Sales at Chain Retailers in a Large Urban Setting.
    Roberto CA; Lawman HG; LeVasseur MT; Mitra N; Peterhans A; Herring B; Bleich SN
    JAMA; 2019 May; 321(18):1799-1810. PubMed ID: 32930704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of the Share of Net Expenditures on Insulin Captured by US Manufacturers, Wholesalers, Pharmacy Benefit Managers, Pharmacies, and Health Plans From 2014 to 2018.
    Van Nuys K; Ribero R; Ryan M; Sood N
    JAMA Health Forum; 2021 Nov; 2(11):e213409. PubMed ID: 35977268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profitability, third-party reimbursement, and access to community pharmacies.
    Carroll NV; Miederhoff PA; Waters LW
    Clin Ther; 1996; 18(4):703-15; discussion 702. PubMed ID: 8879898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacy discounts on generic medicines in France: is there room for further efficiency savings?
    Kanavos P; Taylor D
    Curr Med Res Opin; 2007 Oct; 23(10):2467-76. PubMed ID: 17764613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do higher-priced generic medicines enjoy a competitive advantage under reference pricing?
    Puig-Junoy J
    Appl Health Econ Health Policy; 2012 Nov; 10(6):441-51. PubMed ID: 22900924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between pharmacy benefit managers (PBMs) and the cost of therapies in the US pharmaceutical market: A policy primer for clinicians.
    Schulman KA; Dabora M
    Am Heart J; 2018 Dec; 206():113-122. PubMed ID: 30447542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016.
    Conti RM; Nikpay SS; Buntin MB
    JAMA Netw Open; 2019 Oct; 2(10):e1914141. PubMed ID: 31664442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of a Beverage Tax on Sugar-Sweetened and Artificially Sweetened Beverages With Changes in Beverage Prices and Sales at Chain Retailers in a Large Urban Setting.
    Roberto CA; Lawman HG; LeVasseur MT; Mitra N; Peterhans A; Herring B; Bleich SN
    JAMA; 2019 May; 321(18):1799-1810. PubMed ID: 31087022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.